Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 136,810 | 127,928 | 131,938 | 128,117 | 124,019 |
| Cost of Goods | 22,567 | 20,500 | 26,532 | 24,619 | 23,574 |
| Gross Profit | 114,243 | 107,428 | 105,406 | 103,498 | 100,445 |
| Operating Expenses | 134,862 | 140,849 | 152,842 | 114,608 | 131,973 |
| Operating Income | -20,052 | -32,921 | -46,904 | -10,491 | -30,954 |
| Interest Expense | 603 | 1,725 | 1,930 | 1,837 | 1,925 |
| Other Income | 364 | -9,875 | -1,260 | 567 | 462 |
| Pre-tax Income | -20,291 | -44,521 | -50,094 | -11,761 | -32,417 |
| Income Tax | 1,242 | -4,711 | 2,918 | -6,404 | -411 |
| Net Income Continuous | -21,533 | -39,810 | -53,012 | -5,357 | -32,006 |
| Net Income | $-21,533 | $-39,810 | $-53,012 | $-5,357 | $-32,006 |
| EPS Basic Total Ops | -0.15 | -0.31 | -0.43 | -0.04 | -0.27 |
| EPS Basic Continuous Ops | -0.15 | -0.31 | -0.43 | -0.04 | -0.27 |
| EPS Diluted Total Ops | -0.16 | -0.31 | -0.43 | -0.04 | -0.27 |
| EPS Diluted Continuous Ops | -0.15 | -0.31 | -0.43 | -0.04 | -0.27 |
| EBITDA(a) | $-5,811 | $-20,117 | $-34,613 | $2,513 | $-18,895 |